Tempus Announces Six Abstracts Accepted for Presentation at the 2022 Society for Immunotherapy of Cancer Annual Meeting

Tempus Announces Six Abstracts Accepted for Presentation at the 2022 Society for Immunotherapy of Cancer Annual Meeting

• Download (opens in new window)

Tempus, a leader in artificial intelligence and precision medicine, today announced that six abstracts were accepted for presentation at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting, which convenes in Boston, Massachusetts, from November 8-12, 2022. Tempus continues to be a leader in advancing immunotherapy research, demonstrated in the research presented this year, which includes an oral presentation and five poster presentations.

"The depth of our multimodal data uniquely positions us to support scientific advancement in the field of immuno-oncology," said Calvin Chao, MD, Senior Vice President of Medical Affairs at Tempus. "We continue to make headway in progressing our own research while also supporting the therapeutic research of our collaborators in life sciences."

This year, highlights of Tempus' presented research includes:

• Oral Presentation (#1403): Outcomes following first-line immunotherapy with or without chemotherapy stratified by KRAS mutational status - A real world analysis in patients with advanced NSCLC
  • Session Date & Time: Thursday, November 10, 2022; 7:05 - 7:20 p.m. ET
  • Location: Boston Convention & Exhibition Center, Room 153ABC
  • Overview: This study analyzed real-world data sources to improve understanding of outcomes among patients with advanced NSCLC receiving first-line immunotherapy. This study found that patients' median overall survival varied when treated with immune checkpoint inhibitors depending on their underlying pathogenic KRAS variants including G12C and PD-L1 statuses, ultimately indicating that these patients may benefit from a tailored treatment based on their individual genomic profile.

• Poster Presentation (#43): Tumor mutational burden (TMB) corrected for human leukocyte antigen (HLA) somatic defects predicts response to checkpoint blockade in advanced non-small cell lung cancer
  • Session Date & Time: Thursday, November 10, 2022; 11:40 a.m. - 1:10 p.m. ET, 2:55 - 3:20 p.m. ET, 7:30 - 9:00 p.m. ET
  • Location: Boston Convention & Exhibition Center, Hall C
  • Overview: This study used real-world data to compare the response of two different groups of TMB high NSCLC patients to immune checkpoint blockade therapy. The patients were separated into those with and without HLA loss of heterozygosity (HLA-LOH), and it was determined that TMB high patients with HLA-LOH had a shorter average time to progression when compared to TMB high patients without HLA-LOH.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make near real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.